IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Examiner:

Melissa Jean Perreira

Riou et al.

Art Unit:

1618

Application No.: 10/644,411

Filed: August 20, 2003

Title: Oxindoles Which Are Inhibitors of CDK-1 and Their Application in

Therapeutics

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Applicants submit herewith a list of patents, publications, and other information, and copies thereof as required by 37 C.F.R. 1.98, of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

Further to 37 C.F.R. 1.98(a)(2)(ii), no copy of any listed U.S. patent or publication is provided herewith.

As a convenience to the Examiner, Applicants respectfully point out the following:

U.S. Patent Nos. 6,316,429 and 6,133,305 were cited by the Examiner on PTO Form 892 in the Examiner's Office Action mailed July 26, 2006. These patents are in the same patent family as listed reference WO 98 50356.

U.S. Patent No. 5,792,783, was also cited by the Examiner on PTO Form 892 in the Examiner's Office Action mailed July 26, 2006. This patent is in the same patent family as listed reference WO 96 40116.

This Information Disclosure Statement is being filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311.

The Commissioner is hereby authorized to charge the fee, pursuant to 37 C.F.R. 1.97(c) and 37 C.F.R. 1.17(p), of \$180.00, to Deposit Account 18-1982, upon which the undersigned is authorized to draw. The Commissioner is hereby authorized to charge any underpayment, or credit any overpayment to Deposit Account 18-1982.

57

January 18, 20

Paul R. Darkes Reg. No. 33,862

Attorney for Applicants

Respectfully submitted

sanofi-aventis U.S. LLC
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone 610-889-8458
Telefax 908 231-2626

sanofi-aventis Docket No. ST01004 US CIP

Please type	a plus	sign (+)	inside	this	pox	\rightarrow	/
						-	

Sheet

PTO/SB/08A (10-96)
Approved for use through 10/31/99, OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute	for form 1449A	/PTO		Complete if Known				
				Application Number	10/644,411			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date (08-20-2003			
				First Named Inventor	RIOU			
				Group Art Unit	1618			
(use as many sheets as necessary)				Examiner Name	PERREIRA, Melissa Jean			
Sheet	1	of	2	Attorney Docket Number	ST01004 - US - CIP	,		

U.S. PATENT DOCUMENTS							
Examiner Cite		U.S. Paten	t Document	Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines, Where Relevant	
nitials'	No.1	Number	Kind Code ² (if known)	of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	
		6,313,310		LUK et al	11-06-2001		
		 					
			<u> </u>				
		 -					
							
							
	-				 - 		
		 			+		
		 			 		
			\neg		<u> </u>		
				· · ·	<u> </u>		

		_	FOR	EIGN PATENT DOCUMENT	rs	<u> </u>	
Cite No.1	Office	Foreign Patent Do Number ⁴	Cument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	wo	WO 96/40116	_	TANG et al	12-19-1996		
	wo	WO 98/07695		TANG et al	02-26-1998		
	wo	WO 98/50356		TANG et al	11-12-1998		
	wo	WO 99/62503		EISENBRAND	12-09-1999		
			_				
	<u> </u>						
							1

Examiner	C	Date	
Signature		Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box	[]
Clease type a plus sign (7) maide mis box	1 🗸


PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	ute for form 1449B/PT	0		Complete if Known			
				Application Number	10/644,411		
INFO	ORMATIO	NC	ISCLOSURE	Filing Date	08-20-2003		
STA	TEMENT	BY	APPLICANT	First Named Inventor	RIOU		
• • • • • • • • • • • • • • • • • • • •			7 (1 1 2107 (111)	Group Art Unit	1618		
	(use as many	sheei	's as necessary)	Examiner Name	PERREIRA, Melissa Jean		
Sheet	2	of	2	Attorney Docket Number	ST01004 - US - CIP		

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		KOVAC et al, Furan Derivatives. LXXX. Synthesis and Properties of Substituted Furfurylidenoxindoles, Chem. zvesti 30 (4) 484-492 (1976)	
		SUN et al, Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity Toward Particular Receptor Tyrosine Kinases, J. Med. Chem. 1998, 41, 2588-2603	
Examine Signatur		Date Considered	

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.